

HEATED HIGH FLOW (HHF) CLINICAL PATHWAY

EXECUTIVE SUMMARY

Physician Owner(s): Jason Burrows, M.D.



Primary Objective

Develop a pathway to guide the initiation, escalation, and weaning for patients on heated high flow nasal canula (HFNC).

Recommendations

The use of high flow nasal cannula (HFNC) in the treatment of bronchiolitis has increased dramatically over the last 10 years, with wide variability in HFNC initiation and weaning practices. To date, no prospective studies have successfully predicted which patients will benefit from HFNC, which poses a challenge to creating specific initiation recommendations. There is no national clinical practice guideline to inform the appropriate use of HFNC in the treatment of bronchiolitis.^{1,2,3}

We recommend a HFNC initiation pause (HIP) as a protocol to address patient state – comfort, hunger, hydration, fear, fever, congestion before initiating HFNC in patients with moderate respiratory distress. A recent study utilized this method and reduced HFNC use from 41% to 22%.¹⁴ There was also an overall reduction in LOS by 25%, from 60 to 45 hours. HFNC can be started if a patient clinically worsens because rescue therapy is as effective as early therapy.^{4,5,6} Patients with severe respiratory distress should be initiated on HFNC.

We recommend initial maximum flow rates of 2 L/kg/min (or the 15L maximum) based on observational and physiological studies that suggest these HFNC flow rates may be necessary to unload respiratory muscles, improve work of breathing, or generate positive airway pressure in children with bronchiolitis.⁷⁻¹¹

We recommend weaning or discontinuing HFNC for patients who are clinically improving. The pathway guides RT or RN staff to notify providers when patients on the HFNC pathway have improved respiratory rates, work of breathing, or respiratory scores with low FiO₂ needs to facilitate HFNC weaning. A prior study has shown RT assessments about patient readiness to wean can decrease HFNC therapy duration and LOS.¹² Providers also have the option to directly discontinue HFNC to trial the patient on low flow nasal canula or room air. Trials off HFNC have been demonstrated to decrease LOS and reduce unnecessary time on HFNC.¹³

Intended for patients:

- Age 40 weeks post-conceptual age to less than 2 years
- Any of the following
 - Respiratory distress
 - Hypoxemia (need for > 1L if 30-90 days, > 1.5 L for 91 days - 6 months, > 2L for 6 months – 2 years)
 - Respiratory score (RS) ≥ 5

Exclusion criteria (If using HHF, manage the following patients off this pathway):

- Cardiac disease
- Anatomic airway disease
- Neuromuscular disease

Disclaimer: Pathways are intended as a guide for practitioners and do not indicate an exclusive course of treatment nor serve as a standard of medical care. These pathways should be adapted by medical providers, when indicated, based on their professional judgement, and taking into account individual patient and family circumstances.

HEATED HIGH FLOW (HHF) CLINICAL PATHWAY

EXECUTIVE SUMMARY

Physician Owner(s): Jason Burrows, M.D.



- Immunodeficiency

CLINICAL MANAGEMENT

Prior to Heated High Flow Initiation:

- Obtain RS, suction, repeat RS
 - Moderate Respiratory Distress – Perform HIP (30 min pause) before reassessing
 - HIP supportive care interventions
 - Optimize nasal suctioning
 - Attempt feeds if safe for PO (versus sucrose on pacifier)
 - Encourage parent to the patient, dim the lights
 - Administer an antipyretic for comfort
 - Address hydration needs; consider bolus if clinically dehydrated
 - Consider administration of low-flow nasal cannular (LFNC)
 - For saturation <88% and/or increased work of breathing
 - Pause to let the patient settle
 - Reassess before deciding to initiate HFNC

Initiate Heated High Flow:

- Severe Respiratory Distress or Moderate Respiratory Distress after unsuccessful HIP
- Initiate HHF at a flow rate of 2L/kg/min (max 15L/min and $\geq 30\%$ FiO₂).
- Obtain RS, suction patient, then repeat RS and vital signs per unit routine.
- Place PIV (consider normal saline bolus/IVF)
- Order NPO status

- Provider disposition assessment after 1 hour to determine if patient is clinically worsening or improving. Two licensed providers together at bedside (within 30 mins) may be required should differing opinions on disposition occur.
 - Clinically improving
 - Vital signs per Pediatric Early Warning System (PEWS) policy with suctioning as needed
 - Place NG/OG if anticipated NPO > 1 day (recommend OG for ≤ 5 kg patient)
 - Wean flow rates as tolerated
 - May orally feed when patient is clearly clinically improving based on provider discretion.
 - Clinically unchanged or worsening
 - Notify PICU and arrange patient transfer
 - Manage off pathway

Weaning Heated High Flow:

- FiO₂ should be weaned by RN and/or RT to maintain saturations $\geq 88\%$
- Flow rate should be weaned quickly in improving patients, including at night. RT/RN notify the provider to wean patient's flow rate by at least 1L every 2 hours as long as patient is clinically improving (respiratory distress, respiratory rate) and requiring less than 30% FiO₂

Disclaimer: Pathways are intended as a guide for practitioners and do not indicate an exclusive course of treatment nor serve as a standard of medical care. These pathways should be adapted by medical providers, when indicated, based on their professional judgement, and taking into account individual patient and family circumstances.

HEATED HIGH FLOW (HHF) CLINICAL PATHWAY

EXECUTIVE SUMMARY

Physician Owner(s): Jason Burrows, M.D.



- When flow is stable at 2L for 2 hours, discontinue heated high flow³. Place low flow nasal cannula O₂ if needed to keep saturations $\geq 88\%$.
- Weaning by conducting a trail directly off heated high flow to room air (from any rate) is also possible, as patient's condition allows.

Criteria for Transfer:

- Criteria for transfer to the ICU
 - Clinically worsening on HHF trial
 - Reoccurring apnea > 20 seconds requiring intervention
 - Reoccurring desaturations with increased FiO₂ needs or > 60% FiO₂
 - Altered mental status (irritability, lethargy) poor perfusion (cool extremities, capillary refill > 3 seconds)
- Criteria for transfer from the ICU to the floor
 - Meets pathway criteria, stable on flow rate at or below the floor maximum for ≥ 4 hours AND respiratory score < 8 prior to transfer

Rationale

- Safety Will be maintained by close communication between bedside nurse, charge nurse, RT, and providers.
- Quality: Will be improved by reducing unnecessary variation in initiation, escalation, and weaning of therapy.
- Cost: Will be reduced by reducing variation in treatment which leads to potential delays, adverse events, and readmissions.
- Engagement: Is created and supported by involvement of nursing, respiratory therapy, and providers who care for HHF patients.
- Patient/Family Satisfaction: Shall be improved by providing the highest quality care based on established guidelines and the latest evidence available in the literature.

Implementation Items

- Bronchiolitis Protocol
- Oxygen/Oximetry Protocol
- HHF Equipment Policy
- HHF Order set/Order

Metrics

- Increase HHF order utilization to $\geq 95\%$ for pathway by September 2023. (Process metric)
- Reduce proportion of patients admitted for bronchiolitis initiated on HHF to <45% (bottom Quartile was 25%) by September 2023. (Outcome metric)
- Maintain current length of stay for patients requiring heated high flow during admission <48 hours by September 2023. (Outcome metric)
- Reduce total number of hours of HFNC treatment to < 30 hours (bottom quartile was 32 hours) by September 2023. (Outcome metric)

Disclaimer: Pathways are intended as a guide for practitioners and do not indicate an exclusive course of treatment nor serve as a standard of medical care. These pathways should be adapted by medical providers, when indicated, based on their professional judgement, and taking into account individual patient and family circumstances.

HEATED HIGH FLOW (HHF) CLINICAL PATHWAY

EXECUTIVE SUMMARY

Physician Owner(s): Jason Burrows, M.D.



- Monitor rate of transfers from Med/Surg to the PICU. (Balancing metric)

Team Members

Champion: Jason Burrows, M.D. (Hospitalist)

Members:

- Jay Snow, M.D. (Hospitalist)
- Brenda Weidner, M.D. (Hospitalist)
- Nathaniel Goodrich, M.D. (Hospitalist)
- Hannah Sneller, M.D. (Emergency Medicine Physician)
- Jennifer Wang, D.O (Emergency Medicine Medical Director)
- Matthew Dennis, M.D. (Pulmonologist)
- Andrew MacFadyen, M.D. (Pediatric ICU Physician)
- Katie Niemoller, MSN, RN-BC, CPEN (Nursing Informaticist)
- Stephanie Johnson, RN (Nursing Clinical Education)
- Stacy Salcedo, RN (4th floor Med/Surg Nursing Manager)
- Rachel Shirk, RT (Respiratory Therapy Director)
- Mike Haskins, RT (Respiratory Therapy Inpatient Supervisor)
- Chelsey Marion, RT (Respiratory Therapy Clinical Educator)
- Ellen Kerns, Ph.D. (Care Transformation Data Scientist)
- Kelsey Spackler, DNP, APRN-NP (Clinical Effectiveness)
- Abby Vipond, MSN, FNP-C (Clinical Effectiveness)

Evidence

1. Fujiogi, M., Goto, T., Yasunaga, H., Fujishiro, J., Mansbach, J. M., Camargo, C. A., Jr, & Hasegawa, K. (2019). Trends in Bronchiolitis Hospitalizations in the United States: 2000-2016. *Pediatrics*. 2019;144(6), e20192614.
2. Kalburgi S, Halley T. High-Flow Nasal Cannula Use Outside of the ICU Setting. *Pediatrics*. 2020;146(5):e20194083. doi:10.1542/peds.2019-4083
3. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis [published correction appears in *Pediatrics*. 2015 Oct;136(4):782]. *Pediatrics*. 2014;134(5):e1474-e1502. doi:10.1542/peds.2014-2742
4. Durand P, Guiddir T, Kyheng C, et al. A randomized trial of high-flow nasal cannula in infants with moderate bronchiolitis. *Eur Respir J*. 2020 Jul 16;56(1):1901926
5. Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, Furyk J, Fraser JF, Jones M, Whitty JA, Dalziel SR, Schibler A. A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis. *N Engl J Med*. 2018 Mar 22;378(12):1121-1131. doi: 10.1056/NEJMoa1714855. PMID: 29562151.
6. Kepreotes E, Whitehead B, Attia J, Oldmeadow C, Collison A, Searles A, Goddard B, Hilton J, Lee M, Mattes J. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. *Lancet*. 2017 Mar 4;389(10072):930-939.

Disclaimer: Pathways are intended as a guide for practitioners and do not indicate an exclusive course of treatment nor serve as a standard of medical care. These pathways should be adapted by medical providers, when indicated, based on their professional judgement, and taking into account individual patient and family circumstances.

HEATED HIGH FLOW (HHF) CLINICAL PATHWAY

EXECUTIVE SUMMARY

Physician Owner(s): Jason Burrows, M.D.



7. Pham TM, O'Malley L, Mayfield S, Martin S, Schibler A. The effect of high flow nasal cannula therapy on the work of breathing in infants with bronchiolitis. *Pediatr Pulmonol* 2015 Jul;50(7):713-20.
8. Hough JL, Pham TM, Schibler A. Physiologic effect of high-flow nasal cannula in infants with bronchiolitis. *Pediatric Critical Care Medicine* 2014;15(5):e214-9.
9. González Martínez F, González Sánchez MI, Pérez-Moreno J, Toledo del Castillo B, Rodríguez Fernández R. What is the optimal flow on starting high-flow oxygen therapy for bronchiolitis treatment in paediatric wards? *An Pediatr* 2019.
10. Weiler T, Kamerkar A, Hotz J, Ross PA, Newth CJL, Khemani RG. The relationship between high flow nasal cannula flow rate and effort of breathing in children. *J Pediatr* 2017 Oct;189:66,71.e3.
11. Milesi C, Requirand A, Douillard A, Baleine J, Nogue E, Matecki S, Amedro P, Pons-Odena M, Cambonie G. Assessment of peak inspiratory flow in young infants with acute viral bronchiolitis: Physiological basis for initial flow setting in patients supported with high-flow nasal cannula. *J Pediatr* 2021 Apr;231:239,245.e1.
12. Charvat C, Jain S, Orenstein EW, Miller L, Edmond M, Sanders R. Quality initiative to reduce high-flow nasal cannula duration and length of stay in bronchiolitis. *Hosp Pediatr* 2021 Mar 22.
13. Noelck M, Foster A, Kelly S, Arehart A, Rufener C, Wagner T, Ibsen L, Burns E. SCRATCH trial: An initiative to reduce excess use of high-flow nasal cannula. *Hosp Pediatr* 2021 Apr;11(4):319-26.
14. Treasure, J. D., Lipshaw, M. J., Dean, P., Paff, Z., Arnsperger, A., Meyer, J., Gillen, M., Segev, N., Woeste, L., Mullaney, R., O'Neill, W., Fallon, A., Gildner, C., Brady, P. W., & Statile, A. M. (2023). Quality Improvement to Reduce High-Flow Nasal Cannula Overuse in Children With Bronchiolitis. *Pediatrics*, 152(3), e2022058758. <https://doi.org/10.1542/peds.2022-058758>

Disclaimer: Pathways are intended as a guide for practitioners and do not indicate an exclusive course of treatment nor serve as a standard of medical care. These pathways should be adapted by medical providers, when indicated, based on their professional judgement, and taking into account individual patient and family circumstances.